YD Bio Ltd(YDES)
USD --+0.00%
Reward40Moderate
Risk43Moderate
📊50%Data
Thin -277% profit margin · Revenue growing 96% YoY
YDES
+0.0 · +0.00%
USD · NASDAQ
YD Bio Ltd | Healthcare
Capital Destroyer
Market Cap:605.07M
ℹ️
Reward Rating
40
Moderate
Bottom 10% (model universe)
50% data coverage
ℹ️
Risk Rating
43
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on YDES to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is YD Bio Ltd?

YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs.

YDES · Verdict

Moderate reward · moderate risk

YDES stands out on volatility and balance sheet, but watch the cash flow signal.

Based on 75% data coverage

YDES · Verdict

What’s working & what to watch

Strengths 2

  • Volatility95/100

    Top decile vs peers

  • Balance sheet76/100

    Current ratio 13.18

Watchouts 3

  • Cash flow7/100

    -930% free-cash-flow margin

  • Profitability9/100

    -277% net margin · -43% ROE

  • Valuation41/100

    Below average

Model-based scoring. For information only — not financial advice.

What is YD Bio Ltd?

YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 605.07M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (40)

The scoring profile indicates limited reward potential at this time, with growth and momentum offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap605.07M
P/E RatioN/A
Dividend YieldN/A
52 Week High25
52 Week Low5.3
Last AnnualDecember
IPO Date8/18/2025
IncorporatedUSA
Shares Outstanding71M
No. of EmployeesN/A
IndustryBiotechnology
ExchangeNASDAQ
Beta0.11
CurrencyUSD